News Focus
News Focus
icon url

north40000

11/04/15 3:41 PM

#196840 RE: DewDiligence #196831

AGN will have competition there from Amarin's Vascepa, IMO. I will wager Vascepa is less expensive too...works for me.
icon url

DewDiligence

11/13/15 1:18 PM

#197197 RE: DewDiligence #196831

(AGN)—Auven Therapeutics (private) reports phase-2b/3 data in dry-eye disease:

http://finance.yahoo.com/news/auven-therapeutics-announces-positive-results-123000810.html

Auven’s drug candidate, Seciera, is a proprietary formulation of cyclosporine, which is the active ingredient in AGN’s second-biggest-selling drug, Restasis.